These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25604573)

  • 1. Emerging roles of innate immune signaling and toll-like receptors in fibrosis and systemic sclerosis.
    Bhattacharyya S; Varga J
    Curr Rheumatol Rep; 2015 Jan; 17(1):474. PubMed ID: 25604573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy.
    Bhattacharyya S; Varga J
    Immunol Lett; 2018 Mar; 195():9-17. PubMed ID: 28964818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate immunity and Toll-like receptor signaling in the pathogenesis of scleroderma: advances and opportunities for therapy.
    Brown M; O'Reilly S
    Curr Opin Rheumatol; 2018 Nov; 30(6):600-605. PubMed ID: 30234721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenascin-C in fibrosis in multiple organs: Translational implications.
    Bhattacharyya S; Midwood KS; Varga J
    Semin Cell Dev Biol; 2022 Aug; 128():130-136. PubMed ID: 35400564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate Immunity in Systemic Sclerosis.
    Dowson C; Simpson N; Duffy L; O'Reilly S
    Curr Rheumatol Rep; 2017 Jan; 19(1):2. PubMed ID: 28116578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosis and immune dysregulation in systemic sclerosis.
    Chizzolini C; Brembilla NC; Montanari E; Truchetet ME
    Autoimmun Rev; 2011 Mar; 10(5):276-81. PubMed ID: 20863906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.
    Raschi E; Chighizola CB; Cesana L; Privitera D; Ingegnoli F; Mastaglio C; Meroni PL; Borghi MO
    Arthritis Res Ther; 2018 Aug; 20(1):187. PubMed ID: 30157947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma.
    Bhattacharyya S; Kelley K; Melichian DS; Tamaki Z; Fang F; Su Y; Feng G; Pope RM; Budinger GR; Mutlu GM; Lafyatis R; Radstake T; Feghali-Bostwick C; Varga J
    Am J Pathol; 2013 Jan; 182(1):192-205. PubMed ID: 23141927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate immunity in systemic sclerosis pathogenesis.
    O'Reilly S
    Clin Sci (Lond); 2014 Mar; 126(5):329-37. PubMed ID: 24219159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll Like Receptors in systemic sclerosis: An emerging target.
    O'Reilly S
    Immunol Lett; 2018 Mar; 195():2-8. PubMed ID: 28888416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis.
    Stifano G; Affandi AJ; Mathes AL; Rice LM; Nakerakanti S; Nazari B; Lee J; Christmann RB; Lafyatis R
    Arthritis Res Ther; 2014 Jul; 16(4):R136. PubMed ID: 24984848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like Receptor 9 Signaling Is Augmented in Systemic Sclerosis and Elicits Transforming Growth Factor β-Dependent Fibroblast Activation.
    Fang F; Marangoni RG; Zhou X; Yang Y; Ye B; Shangguang A; Qin W; Wang W; Bhattacharyya S; Wei J; Tourtellotte WG; Varga J
    Arthritis Rheumatol; 2016 Aug; 68(8):1989-2002. PubMed ID: 26946325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung.
    Bhattacharyya S; Wang W; Qin W; Cheng K; Coulup S; Chavez S; Jiang S; Raparia K; De Almeida LMV; Stehlik C; Tamaki Z; Yin H; Varga J
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling.
    Bhattacharyya S; Tamaki Z; Wang W; Hinchcliff M; Hoover P; Getsios S; White ES; Varga J
    Sci Transl Med; 2014 Apr; 6(232):232ra50. PubMed ID: 24739758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis.
    Bhattacharyya S; Wang W; Tamaki Z; Shi B; Yeldandi A; Tsukimi Y; Yamasaki M; Varga J
    Front Immunol; 2018; 9():2434. PubMed ID: 30405628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of innate immune system in systemic sclerosis.
    Fullard N; O'Reilly S
    Semin Immunopathol; 2015 Sep; 37(5):511-7. PubMed ID: 26159672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of toll-like receptors in systemic sclerosis.
    Ciechomska M; Cant R; Finnigan J; van Laar JM; O'Reilly S
    Expert Rev Mol Med; 2013 Aug; 15():e9. PubMed ID: 23985302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toll-like receptors in mediating pathogenesis in systemic sclerosis.
    Frasca L; Lande R
    Clin Exp Immunol; 2020 Jul; 201(1):14-24. PubMed ID: 32048277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.
    Bhattacharyya S; Wei J; Varga J
    Nat Rev Rheumatol; 2011 Oct; 8(1):42-54. PubMed ID: 22025123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4.
    Fineschi S; Goffin L; Rezzonico R; Cozzi F; Dayer JM; Meroni PL; Chizzolini C
    Arthritis Rheum; 2008 Dec; 58(12):3913-23. PubMed ID: 19035500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.